TrKA kinase inhibitors, compositions and methods thereof

Patent metadata

Field	Value
Publication number	US-9914736-B2
Application number	US-201515128782-A
Country	US
Kind code	B2
Filing date	Mar 23, 2015
Priority date	Mar 26, 2014
Publication date	Mar 13, 2018
Grant date	Mar 13, 2018

Abstract

The present invention is directed to substituted five membered heteroaryl benzamide compounds of formula (I) (Formula (I)) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence are useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.

First claim

What is claimed is:

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein
B represents a five membered heteroaryl having at least one heteroatom that is nitrogen, wherein said heteroaryl is pyrazolyl optionally substituted with 1 to 3 groups of R a ;
R represents hydrogen, OH, or —C 1-6 alkyl;
R 1 and R 5 are independently selected from the group consisting of hydrogen, CN, OH, and halogen;
one of R 2 and R 4 is hydrogen, and the other is (CHR) n C 6-10 aryl and (CHR) n C 5-10 heterocycle, said aryl, optionally substituted with 1 to 3 groups of R a , said heterocycle selected from the group consisting of pyrazolyl, pyridyl, thiazolyl, triazolyl, oxazolyl, pyrimidinyl, pyridazinyl, pyrazinyl, oxadiazolyl, and thiadiazolyl each of said heterocycle groups optionally substituted with 1 to 3 groups of R a
R 3 represents C 1-4 haloalkyl, and —OC 1-4 haloalkyl;
R a is selected from the group consisting of —CN, NO 2 , —C 1-4 haloalkyl, —OC 1-4 haloalkyl, —C 1-6 alkyl, —C 1-6 alkenyl, —C 1-6 alkynyl, —(CHR) n C 6-10 aryl, —(CHR) n C 4-10 heterocycle,
—(CHR) n C(O)(CHR) n C 4-10 heterocycle, —O—(CH 2 ) n C 6-10 aryl, —O—(CH 2 ) n C 4-10 heterocycle —O—, —(CH 2 ) n N(R d ) 2 , —(CH 2 ) n C(O)NH(CH 2 ) n C 4-10 heterocycle, SO 2 R d , SO 2 N(R d ) 2 , —C(O)CF 3 , COR, —(CH 2 ) n halo, —(CH 2 ) n NHC(O)R d , —(CH 2 ) n NHC(O)NHR d , —(CH 2 ) n C(O)ON(R d ) 2 , —(CH 2 ) n NHC(O)OR d , —(CHR) n C(O)N(R d ) 2 , —OC 1-6 alkyl, and —OH, said alkyl, aryl and heterocycle optionally substituted with 1 to 3 groups of R b , wherein when two R d groups are attached to a nitrogen atom they may optionally combine with that nitrogen to from a 4-8 membered heterocyle that is optionally substituted with 1 to 3 groups of R f , or two R a groups when present on a ring can be linked together to form a 4-8 membered heterocycle that is optionally substituted with 1 to 3 groups of R f ;
R b is selected from the group consisting of —C 1-6 alkyl, —C 1-6 alkylOR, —C 1-4 haloalkyl, —(CH 2 ) n C 3-6cyclo alkyl, —(CH 2 ) n N(R d ) 2 , —(CH 2 ) n OR c , —O—, halogen, —CN, S(O)(NH)Rg, —SO 2 R, —SO 2 N(R d ) 2 , —O—(CH 2 ) n C 4-10 heterocycle, —(CH 2 ) n C(O)N(R d ) 2 , —(CH 2 ) n NHC(O)R d , —C 1-6 alkylN(R d ) 2 , and halo, said cycloalkyl and heterocycle optionally substituted with 1 to 3 groups of R f , and wherein when two R d groups are attached to a nitrogen atom they may combine with that nitrogen to from a 4-8 membered heterocyle that is optionally substituted with 1 to 3 groups of R f ;
R c is selected from the group consisting of hydrogen, —C 1-6 alkylORg, —C 1-4 haloalkyl and —C 1-6 alkyl
R d is independently selected from the group consisting of hydrogen, —C 1-4 haloalkyl —C 1-6 alkyl, —(CH 2 ) n NR f C 4-10 heterocycle, —(CH 2 ) n C 3-6cyclo alkyl, and —(CH 2 ) nC4-10heterocycle said alkyl, cycloalkyl and heterocycle optionally substituted with 1 to 3 groups of Rf;
R f is selected from the group consisting of hydrogen, —C 1-6 alkyl, OR c , CN, —N(R c ) 2 , C(O)N(Rg) 2 , C(O)C 1-6 alkyl, —SO 2 Rg, —O—, —C 1-6 alkylSO 2 Rg, —C 1-6 alkylORg, —C 1-6 alkylN(Rg) 2 ,
Rg is selected from the group consisting of hydrogen, —C 1-6 alkyl; and
n represents 0-6.

2. The compound according to claim 1 wherein one of R 2 and R 4 is hydrogen and the other is (CHR) n C 5-10 heterocycle, said heterocycle optionally substituted 1 to 3 groups of R a .

3. The compound according to claim 2 wherein the heterocycle is R 2 and R 4 selected from the group consisting of pyrazolyl, pyridyl, and pyrimidinyl, said groups optionally substituted with 1 to 3 groups of R a .

4. The compound according to claim 3 wherein the heterocycle of R 2 and R 4 is pyrazolyl optionally substituted with 1 to 3 groups of R a .

5. The compound according to claim 1 wherein B is represented by structural formula (a), (b), or (i):

wherein:
R 7 is selected from the consisting of hydrogen, C 1-6 alkyl, C(O)C 1-6 alkyl, C 6-10 aryl, and C 5-10 heterocycle, said alkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a ; and R 8 and R 9 are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C(O)N(R) 2 , (CH 2 ) n NH(CH 2 ) n OR, (CH 2 ) n C(O)NH(CH 2 ) n C 3-10 cycloalkyl, C(O)R, (CH 2 ) n C 6-10 aryl, (CH 2 ) n C(O)NH(CH 2 ) n C 6-10 aryl, (CH 2 ) n C 5-10 heterocycle, and (CH 2 ) n C(O)NH(CH 2 ) n C 5-10 heterocycle, said alkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a .

6. The compound according to claim 5 wherein one of R 8 and R 9 is selected from hydrogen, C 1-6 alkyl, and C 6-10 aryl and the other is selected from C 1-6 alkyl, C(O)N(R) 2 , (CH 2 ) n NH(CH 2 ) n OR, (CH 2 ) n C(O)NH(CH 2 ) n C 3-10 cycloalkyl, C(O)R, (CH 2 ) n C 6-10 aryl, (CH 2 ) n C(O)NH(CH 2 ) n C 6-10 aryl, (CH 2 ) n C 5-10 heterocycle, and (CH 2 ) n C(O)NH(CH 2 ) n C 5-10 heterocycle, said alkyl, cycloalkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a .

7. The compound according to claim 6 wherein when for R 8 and R 9 the alkyl is selected from the group consisting of optionally substituted methyl, ethyl, propyl, and butyl, the aryl is optionally substituted phenyl, and the heterocycle is selected from the group consisting of optionally substituted pyrazolyl, tetrazolyl, pyridyl, pyridazinyl, triazolyl, pyrimidinyl, azetidinyl, pyrrolidinyl, isothiazolyl, and thiazolyl.

8. The compound according to claim 5 wherein R 7 is selected from the group consisting of hydrogen, methyl, ethyl, pyrazolyl, and phenyl, said methyl, ethyl, pyrazolyl and phenyl optionally substituted with 1 to 3 groups of R a .

9. The compound according to claim 1 of formula I represented by structural formula II or III:

or pharmaceutically acceptable salts thereof, wherein one of R 2 and R 4 is hydrogen and the other is (CHR) n C 5-10 heterocycle, selected from the group consisting of pyrazolyl, pyridyl, and pyrimidinyl, each of said heterocycle groups optionally substituted with 1 to 3 groups selected from the groups consisting of —(CH 2 ) n C 1-4 haloalkyl, —OC 1-4 haloalkyl, —C 1-6 alkyl, —C(O)CF 3 , —(CH 2 ) n halo, and —OR, the n in (CHR) n C 5-10 heterocycle of R 2 and R 4 is 0, R 3 is CF 3 , OCF 3 , R 7 is C 1-6 alkyl, C 6-10 aryl, or C 5-10 heterocycle, said alkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a ; and R 8 and R 9 are independently selected from hydrogen, C 1-6 alkyl, C(O)N(R) 2 , (CH 2 ) n NH(CH 2 ) n OR, (CH 2 ) n C(O)NH(CH 2 ) n C 3-10 cycloalkyl, C(O)R, (CH 2 ) n C 6-10 aryl, (CH 2 ) n C(O)NH(CH 2 ) n C 6-10 aryl, (CH 2 ) n C 5-10 heterocycle, and (CH 2 ) n C(O)NH(CH 2 ) n C 5-10 heterocycle, said alkyl, aryl, and heterocycle optionally substituted with 1 to 3 groups of R a .

10. The compound according to claim 9 wherein R 7 is phenyl, or pyrazolyl, said phenyl and pyrazolyl optionally substituted with 1 to 3 groups of R a R 8 and R 9 are independently selected from the groups consisting of hydrogen, methyl, ethyl, propyl, butyl, phenyl, pyrazolyl, tetrazolyl, pyridyl, pyridazinyl, triazolyl, pyrimidinyl, azetidinyl, pyrrolidinyl, isothiazolyl, and thiazolyl said methyl, ethyl, propyl, butyl, phenyl, pyrazolyl, tetrazolyl, pyridyl, pyridazinyl, triazolyl, pyrimidinyl, azetidinyl, pyrrolidinyl, isothiazolyl, and thiazolyl optionally substituted with 1 to 3 groups of R a .

Assignees

• Merck Sharp & Dohme

Inventors

• Mitchell Helen
• Fraley Mark E
• Cooke Andrew J
• Stump Craig A
• Zhang Xu-Fang
• Mccomas Casey C
• Schirripa Kathy
• Mcwherter Melody
• Liu Ping
• Parker Dann
• Li Chun Sing
• Mao Qinghua

Classifications

• C07D417/14

  containing three or more hetero rings · CPC title

• C07D417/12

  linked by a chain containing hetero atoms as chain links · CPC title

• C07D413/14

  containing three or more hetero rings · CPC title

• C07D403/14

  containing three or more hetero rings · CPC title

• C07D403/04

  directly linked by a ring-member-to-ring-member bond · CPC title